Give them an effective treatment
they may not have tried before
ACZONE® (dapsone) Gel 7.5% 90 gram bottle

Understanding your acne patients

Prevalence of acne reported by age group and gender1,*

Prevalence of acne reported by age group and gender

*Results of a survey completed by 1,013 participants aged 20 years or older. Survey questions included whether the participant had ever had acne or pimples; had acne or pimples during their teenage years; and had acne in their 20s, 30s, 40s, and 50s or older. Participants' mean age was 48; 540 were female and 473 were male.

  • Adult acne is more common in females than in males and presents differently than adolescent acne1
  • Presents on chin, lower third of face, jawline, and neck2,3
  • Inflammatory in nature; hormonal flares are common2,3
  • Commonly persistent in females, continuing from adolescence into adulthood2

Patient experience: female

Female patients have rated visible red bumps as a top concern9,*
By the time they see a dermatologist, female patients have tried 12+ products on average9,*
Female patients are more likely to think about their acne "often" during the day compared to males9,*
Mature female skin may be more predisposed to irritation with certain topical treatments10
Female patients account for two-thirds of visits made to dermatologists for acne11
Some acne treatments can damage clothing10
Nearly 80% of surveyed women with acne would like to be contacted by their doctor’s office to ask whether their medication is working12,†
*A total of 310 acne patients, 190 of whom were females aged 16 to 45 years, completed an Internet survey conducted between December 11, 2013, and January 3, 2014.
A total of 400 female patients with acne, 200 of whom were aged 16 to 24 and 200 of whom were aged 25 to 50, completed an online survey conducted in October 2016.
  • Adolescent acne is more common in male patients than in female patients1,4
  • Presents on cheeks and trunk2,5,6
  • Comedonal and inflammatory in nature2
  • May be more prone to higher sebum production7,8

Patient experience: male

Teen males want to know what type of acne they have and what causes it13,*
Discussing treatment options with their dermatologist is a top priority for teen males9,†
Half of teen male patients surveyed said they want a prescription product with an ingredient they haven’t tried before13,*
The most common reason male patients stop using an acne medication is because it did not clear their acne9,†
Almost two-thirds of teen males use their acne treatment as prescribed. Forgetting was the top reason for not using all medications as prescribed13,*
*Seventy-five male acne patients aged 14 to 18 years under a dermatologist’s care completed online interviews in October 2015.
A total of 310 acne patients, 120 of whom where males aged 16 to 45 years, completed an Internet survey between December 11, 2013 and January 3, 2014.
Patients turn to you for answers

...help finding the best treatment that fits my skin

Typical acne patient, age 27

...skin care that would suit me the best and treat my acne

Typical acne patient, age 29

...a product for my type of acne

Typical acne patient, age 38

...something I haven't tried before

Typical acne patient, age 32

INDICATIONS AND USAGE

ACZONE® (dapsone) Gel 7.5% is indicated for the topical treatment of acne vulgaris in patients aged 12 years and older.

IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS

Hematological Effects
Methemoglobinemia: Cases of methemoglobinemia with resultant hospitalization have been reported post marketing in association with twice-daily dapsone gel 5% treatment. Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia. Avoid use of ACZONE® Gel 7.5% in patients with congenital or idiopathic methemoglobinemia.

Signs and symptoms of methemoglobinemia may be delayed some hours after exposure. Initial signs and symptoms of methemoglobinemia are characterized by a slate-gray cyanosis seen in, eg, buccal mucous membranes, lips, and nail beds. Advise patients to discontinue ACZONE® Gel 7.5% and seek immediate medical attention in the event of cyanosis.

Dapsone can cause elevated methemoglobin levels, particularly in conjunction with methemoglobin-inducing agents.

Hemolysis: Oral dapsone treatment has produced dose-related hemolysis and hemolytic anemia. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are more prone to hemolysis with the use of certain drugs. G6PD deficiency is most prevalent in populations of African, South Asian, Middle Eastern, and Mediterranean ancestry.

In clinical trials, there was no evidence of clinically relevant hemolysis or hemolytic anemia in subjects treated with topical dapsone. Some subjects with G6PD deficiency using dapsone gel 5% twice daily developed laboratory changes suggestive of hemolysis.

Discontinue ACZONE® Gel 7.5% if signs and symptoms suggestive of hemolytic anemia occur. Avoid use of ACZONE® Gel 7.5% in patients who are taking oral dapsone or antimalarial medications because of the potential for hemolytic reactions. Combination of ACZONE® Gel 7.5% with trimethoprim/sulfamethoxazole (TMP/SMX) may increase the likelihood of hemolysis in patients with G6PD deficiency.

Peripheral Neuropathy
Peripheral neuropathy (motor loss and muscle weakness) has been reported with oral dapsone treatment. No events of peripheral neuropathy were observed in clinical trials with topical dapsone treatment.

Skin Reactions
Skin reactions (toxic epidermal necrolysis, erythema multiforme, morbilliform and scarlatiniform reactions, bullous and exfoliative dermatitis, erythema nodosum, and urticaria) have been reported with oral dapsone treatment. These types of skin reactions were not observed in clinical trials with topical dapsone treatment.

ADVERSE REACTIONS

The most common adverse reactions of ACZONE® Gel 7.5% are dryness and pruritus at the application site.

Methemoglobinemia has been identified during postmarketing use of topical dapsone.

DRUG INTERACTIONS

Topical application of dapsone gel followed by benzoyl peroxide in patients with acne vulgaris may result in a temporary local yellow or orange discoloration of the skin and facial hair.

Please see ACZONE® Gel full Prescribing Information.

References:

1. Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older [published correction appears in J Am Acad Dermatol. 2008;58(5):874]. J Am Acad Dermatol. 2008;58(1):56-59. 2. Holzmann R, Shakery K. Postadolescent acne in females. Skin Pharmacol Physiol. 2014;27(suppl 1):3-8. 3. Dréno B. Treatment of adult female acne: a new challenge. J Eur Acad Dermatol Venereol. 2015;29(suppl 5):4‑19. 4. Khunger N. Kumar C. A clinico-epidemiological study of adult acne: is it different from adolescent acne? Indian J Dermatol Venereol Leprol. 2012;78(3):335-341. 5. Kaur S, Verma P Sangwan A, Dayal S, Jain VK. Etiopathogenesis and therapeutic approach to adult onset acne. Indian J Dermatol. 2016;61(4):403-407. 6. Goulden V, Clark SM, Cunlifle WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol. 1997;136(1):66-70. 7. McCarty M. Evaluation and management of refractory acne vulgaris in adolescent and adult men. Dermatol Clin. 2016;34(2):203-206. 8. Kim BY, Choi JW, Park K, Youn SW Sebum, acne, skin elasticity, and gender difference—which is the major influencing factor for facial pores? Skin Res Technol. 2013;19(1):e45-e53. 9. Data on file, Allergan, January 10, 2014; Defining Acne Treatment: Final Report. 10. Dréno B, Layton A, Zouboulis CC, et al. Adult female acne: a new paradigm. J Eur Acad Dermatol Venereol. 2013;27(9):1063-1070. 11. Kamangar F, Shinkai K. Acne in the adult female patient: a practical approach. Int J Dermatol. 2012;51(10):1162-1174. 12. Data on file, Allergan, November 14, 2016; Acne Patient Insights Research. 13. Data on file, Allergan, October 2015; Teen Boy Acne Conversation Tool Report.

ACZONE® (dapsone) Gel, 7.5% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
INDICATIONS AND USAGE

ACZONE® (dapsone) Gel 7.5% is indicated for the topical treatment of acne vulgaris in patients aged 12 years and older.

IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS

Hematological Effects
Methemoglobinemia: Cases of methemoglobinemia with resultant hospitalization have been reported post marketing in association with twice-daily dapsone gel 5% treatment. Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methemoglobinemia are more susceptible to drug-induced methemoglobinemia. Avoid use of ACZONE® Gel 7.5% in patients with congenital or idiopathic methemoglobinemia.

Signs and symptoms of methemoglobinemia may be delayed some hours after exposure. Initial signs and symptoms of methemoglobinemia are characterized by a slate-gray cyanosis seen in, eg, buccal mucous membranes, lips, and nail beds. Advise patients to discontinue ACZONE® Gel 7.5% and seek immediate medical attention in the event of cyanosis.

Dapsone can cause elevated methemoglobin levels, particularly in conjunction with methemoglobin-inducing agents.

Hemolysis: Oral dapsone treatment has produced dose-related hemolysis and hemolytic anemia. Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are more prone to hemolysis with the use of certain drugs. G6PD deficiency is most prevalent in populations of African, South Asian, Middle Eastern, and Mediterranean ancestry.

In clinical trials, there was no evidence of clinically relevant hemolysis or hemolytic anemia in subjects treated with topical dapsone. Some subjects with G6PD deficiency using dapsone gel 5% twice daily developed laboratory changes suggestive of hemolysis.

Discontinue ACZONE® Gel 7.5% if signs and symptoms suggestive of hemolytic anemia occur. Avoid use of ACZONE® Gel 7.5% in patients who are taking oral dapsone or antimalarial medications because of the potential for hemolytic reactions. Combination of ACZONE® Gel 7.5% with trimethoprim/sulfamethoxazole (TMP/SMX) may increase the likelihood of hemolysis in patients with G6PD deficiency.

Peripheral Neuropathy
Peripheral neuropathy (motor loss and muscle weakness) has been reported with oral dapsone treatment. No events of peripheral neuropathy were observed in clinical trials with topical dapsone treatment.

Skin Reactions
Skin reactions (toxic epidermal necrolysis, erythema multiforme, morbilliform and scarlatiniform reactions, bullous and exfoliative dermatitis, erythema nodosum, and urticaria) have been reported with oral dapsone treatment. These types of skin reactions were not observed in clinical trials with topical dapsone treatment.

ADVERSE REACTIONS

The most common adverse reactions of ACZONE® Gel 7.5% are dryness and pruritus at the application site.

Methemoglobinemia has been identified during postmarketing use of topical dapsone.

DRUG INTERACTIONS

Topical application of dapsone gel followed by benzoyl peroxide in patients with acne vulgaris may result in a temporary local yellow or orange discoloration of the skin and facial hair.

Please see ACZONE® Gel full Prescribing Information.